Sign in
CompletedNo phase

Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices

Key facts

Who runs it
Institute of Liver and Biliary Sciences, India
Where
India1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
104 people enrolled
Started
1 Oct 2021
Ended
31 Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Carvedilol
  • Standard Medical Treatment
Record updated
20 March 2025

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Age 18-65 years
  • Liver cirrhosis
  • Grade II-III high SAAG ascites
  • Small low risk or no esophageal varices
  • CTP 7-12

Who cannot take part

  • AKI at enrollement (Prior transient volume responsive AKI stage I included)
  • Post renal or liver transplantation
  • Prior intolerance or S/E to carvedilol or diuretics
  • History of CAD, PVD, ventricular arrythmia, Bronchial asthma
  • Bilirubin >5 mg/dl
  • Age <18 years
  • SBP at diagnosis
  • Severe Hyponatremia (Na <125 MEq/L)
  • Grade II/III/IV HE
  • Advanced HCC (BCLC C,D), PVTT, Pregnancy or Lactating mother
  • High risk varices (Large varices or small high risk varices)
  • CTP >12
  • ACLF
  • Mixed / TB ascites
  • Known CKD, obstructive uropathy
  • Patient on MV, NIV, systemic sepsis and shock
  • Lack of informed consent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The cumulative risk of refractory ascites is in the order of 20% within five years of the development of ascites. An elevated sinusoidal pressure is essential for the development of ascites, as fluid accumulation does not develop at portal pressure gradient below 8 mm Hg, and rising corrected sinusoidal pressure correlates with decreased 24-hour urinary excretion of sodium.More recently, it has been hypothesised that bacterial translocation associated with portal hypertension in cirrhosis and related pathogen-associated, molecular pattern activated innate immune responses lead to systemic inflammation.This is associated with vasodilatation as well as release of proinflammatory cytokines, reactive oxygen and nitrogen species, contributing to organ dysfunction.This activates sympathetic nervous system stimulating reabsorption of sodium in proximal,distal tubules, loop of Henle and collecting duct as well as the renin-angiotensin-aldosterone system, leading to sodium absorption from distal tubule and collecting duct.[5]Renal sodium retention and eventual free water clearance due to non-osmoticrelease of arginine-vasopressin and its action on V2 receptor in the collectingduct underlie the fluid retention associated with oedema and ascites in cirrhosis.The lowering of portal pressure using non selective beta blocker has also been shown to reduce the development of ascites, refractory ascites and hepatorenal syndrome.Furthermore, the effect of non slective beta blocker on intestinal permeability, bacterial translocation and inflammatory response has been proposed to mitigate the risk of developing spontaneous bacterial peritonitis.

The 2 groups in the trial

  • Carvedilol with Standard Medical TreatmentTreatment being tested

    Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP \>90, HR \>55.

    Treatment: Carvedilol and Standard Medical Treatment

  • Standard Medical TreatmentExisting treatment, for comparison

    \- Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices- A Randomised Controlled Trial"
Publications
Record updated
20 March 2025